MedPath

X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure

Phase 4
Terminated
Conditions
Heart Failure, Congestive
Registration Number
NCT00157846
Lead Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Brief Summary

The goal of X-Change HF is to estimate the effect of biventricular stimulation in patients who need antibradycardia ventricular stimulation (more than 80%); are eligible for the exchange of an old pacemaker or implantable cardioverter defibrillator (ICD); and have ventricular dysfunction (left ventricular ejection fraction \[LVEF\] \< 35%). All patients eligible for participation in the study will be upgraded with a cardiac resynchronization therapy (CRT)-device and receive either right ventricular or biventricular stimulation in a crossover protocol. The endpoint is functional performance measured by spiroergometry.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Implanted dual-chamber pacemaker or ICD system with replacement indication

    • Because of battery end of life

    • Because of upgrade from pacemaker to ICD system

      • predominant sinus rhythm (paroxysmal atrial fibrillation [AF] < 2 hours/day)
      • predominant ventricular stimulation (>= 80%)
      • NYHA Class II-III
      • LVEF <= 35%
Exclusion Criteria
  • NYHA Class IV

  • Life expectancy of less than one year because of accompanying diseases

  • Myocardial infarction less than 3 months old

  • Cardiac surgery less than 3 months

    • Bypass
    • Valve surgery
    • Percutaneous transluminal coronary angioplasty (PTCA)
  • Thoracotomy, for implant of an epicardial LV electrode

  • Medical circumstances that make participation and compliance impossible

  • Patients who are not willing or able to give written consent for their study participation

  • Participation in another study

  • Patients less than 18 years old

  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Cardiopulmonary performance measured by spiroergometryBaseline to 7 months post-implant

Maximal oxygen uptake (Vo2 max \[ml/kg/min\])

Secondary Outcome Measures
NameTimeMethod
Heart rate variability [ms]Baseline to 7 months post implant
Amount of hospitalizations because of heart failure (amount and duration [days])Baseline to 7 months post-implant
Cardiopulmonary performance measured by spiroergometry: Oxygen uptake at the anaerobic threshold (VO2 AT [s])Baseline to 7 months post-implant
N-terminal prohormone brain natriuretic peptide (NT-proBNP) [pg/ml]Baseline to 7 months post-implant
Left ventricular ejection fraction (LVEF [%])Baseline to 7 months post-implant
New York Heart Association (NYHA) ClassBaseline to 7 months post-implant
Occurrence of rhythm disturbances: atrial arrhythmias (amount and duration [h/day])Baseline to 7 months post-implant
Left ventricular end diastolic diameter (LVEDD [mm])Baseline to 7 months post-implant
MortalityBaseline to 7 months post-implant
Occurrence of rhythm disturbances: ventricular arrhythmias (amount and duration [h/day])Baseline to 7 months post-implant

Trial Locations

Locations (10)

Klinikum Augsburg I. Medizinische Klinik

🇩🇪

Augsburg, Germany

Charite Campus Virchow-Klinikum

🇩🇪

Berlin, Germany

Unfallkrankenhaus Benjamin Franklin

🇩🇪

Berlin, Germany

Ev. Freikirchliches KH Bernau und Herzzentrum Brandenburg

🇩🇪

Bernau, Germany

Berufsgenossenschaftliche Kliniken Bergmannsheil

🇩🇪

Bochum, Germany

Städtisches Kreiskrankenhaus

🇩🇪

Friedrichshafen, Germany

Georg-August-Universität Göttingen

🇩🇪

Göttingen, Germany

St.-Vincentius Klinken

🇩🇪

Karlsruhe, Germany

Märkische Kliniken GmbH Klinikum Luedenscheid

🇩🇪

Luedenscheid, Germany

Krankenhaus Reinbek St. Adolf Stift

🇩🇪

Reinbek B. Hamburg, Germany

Klinikum Augsburg I. Medizinische Klinik
🇩🇪Augsburg, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.